The Cold-EEZE line includes over-the-counter cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the U.S. With the acquisition, Mylan has received global rights – including all U.S. rights and international trademarks – for these products.
"The completion of this transaction is an important step as we continue to expand our consumer health care offerings,” Mylan CEO Heather Bresch said in a statement. “Cold-EEZE is now Mylan's largest U.S. consumer health care brand and is part of a growing portfolio of over-the-counter products in the U.S. Mylan is committed to providing access to the medications that patients need, whether they are in front of or behind the pharmacy counter. We look forward to serving this loyal customer base and supporting this well-known brand."
Mylan, a global pharmaceutical company, noted in its press release that it is committed to developing new health care standards and aims to improve access to high quality medicine to all of this world’s inhabitants.